Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms Galium 68 VMT 02, VMT 02, VMT-02 + [1] |
Target |
Action antagonists |
Mechanism MC1R antagonists(Melanocortin receptor 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Phase 2 | United States | - | |
| Melanoma, Cutaneous Malignant | Phase 1 | United States | 05 Mar 2021 | |
| Metastatic melanoma | Phase 1 | United States | 05 Mar 2021 | |
| Mucosal Melanoma | Phase 1 | United States | 05 Mar 2021 | |
| Uveal Melanoma | Phase 1 | United States | 05 Mar 2021 |





